| EBITDA Margin: guided vs achieved | 28.00% achieved Guided 25.00%–27.00%, 3.7% above the top of the range; confirmed by management |
|---|---|
| Management target | Revenue 100.0% 2030 |
| Revenue growth | 30.3% YoY Consolidated; 12.3% YoY Standalone. |
|---|---|
| Margins | Standalone EBITDA margins improved 154 bps YoY to 28.0%. |
| Demand visibility | Strong growth in domestic cardiology and international trauma implants. |
| Management confidence | High; citing 'Polymed 3.0' exponential growth phase. |
Growth
Consolidated Revenue grew 30.3% YoY to ₹525.4 Cr. Standalone Operating EBITDA grew 18.8% YoY with 28% margins.
Outlook
Vision 2030 targets 2x revenue with industry-leading margins; 2 upcoming plants and 25-30 new product launches planned.
Risks
West Asia crisis caused 32% degrowth in Middle East markets; domestic renal business faces Chinese pricing pressure.
Last quarter's promises, checked
Delivered
- H2 revenue 20% above H1 → delivered 21% (= BEAT)
- Standalone EBITDA margin 25-27% → delivered 26.8% (= BEAT)
- Placing 450 dialysis machines → delivered 450 (= BEAT)
Partly delivered
- Launch 35 new products → delivered 35 including acquisitions (= PARTIAL)
Missed
- Standalone revenue growth mid-teens → delivered 4-5% (= MISS)
Investor Presentation filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,724.40
- Market cap
- ₹17,479 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 55.5×Sector 57.8×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Earnings Call Transcript: Key Takeaways
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
- Call
- Guides 100% growth
Poly Medicure Q1 FY27 Results: Net Profit ₹85.3 Cr, Down 8.4% YoY
Poly Medicure Ltd reported revenue from operations of ₹525.4 Cr (+30.3% YoY) and net profit of ₹85.3 Cr (-8.4% YoY) for Q1 FY27.
- Key figure
- Net profit ₹85.3 Cr · -8.4% YoY
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure reported FY26 consolidated revenue of ₹1,875cr (up 12.3%) and standalone EBITDA of ₹446cr (26.8% margin). The company is transitioning from product-focused to therapy-focused segments like Cardiology and Renal.
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure delivered solid revenue growth despite geopolitical and raw material headwinds, successfully pivoting towards high-margin oncology, renal, and cardiology segments while integrating key acquisitions.
Poly Medicure Earnings Call: Key Takeaways
Poly Medicure (Polymed) reported FY26 consolidated revenue growth of 12.3% YoY. The company is transitioning towards high-end technology segments like Cardiology and Orthopaedics through strategic European acquisitions (Citieffe, PendraCare).